Immune Checkpoint Blockade and Interferon-α in Melanoma

被引：33

作者：

Rafique, Imran ^{[1
]}

Kirkwood, John M. ^{[1
,2
]}

Tarhini, Ahmad A. ^{[1
,2
]}

机构：

[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15232 USA

[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15232 USA

来源：

SEMINARS IN ONCOLOGY | 2015年 / 42卷 / 03期

关键词：

CD8; T-CELLS; ANTIGEN; 4; CTLA-4; DOSE INTERFERON-ALPHA-2B; MONOCLONAL-ANTIBODY; PHASE-I; COMBINATION IMMUNOTHERAPY; PROGRAMMED CELL-DEATH-1; ANTI-CTLA4; ANTIBODY; CLINICAL ACTIVITY; SUPPRESSOR-CELLS;

D O I：

10.1053/j.seminoncol.2015.02.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The quality of the host immune response in patients with advanced melanoma is compromised with a bias towards Th2-type polarization and a tumor microenvironment that facilitates disease progression. Overcoming tumor-induced immune suppression through strategies that build upon the immunomodulatory qualities and clinical activity of interferon-a as demonstrated in the Melanoma adjuvant setting is a major clinical need. The recent advances in the field of immune checkpoint modulation and the unprecedented clinical activity in advanced melanoma opens the door on novel combinations that may overcome tumor tolerogenic mechanisms that are known to suppress the potent anti-tumor impact of interferon (IFN)-alpha. Promising preliminary data suggest that such combinations may move the clinical management of advanced melanoma into the next level, beyond what is currently seen with immune checkpoint blockers alone. (C) 2015 Elsevier Inc. All rights reserved.

引用

页码：436 / 447

页数：12

共 93 条

[1]

[Anonymous], 2014, J CLIN ONCOL

[2]

[Anonymous], SEMIN ONCOL

[3]

[Anonymous], IN J CLIN ONCOL S

[4] Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. [J].

Atkins, Michael B. ;

Reiney, Ragini ;

Sznol, Kudchadkar Mario ;

McDermott, David F. ;

Lotem, Michal ;

Schachter, Jacob ;

Wolchok, Jedd D. ;

Urba, Walter John ;

Kuzel, Timothy ;

Schuchter, Lynn Mara ;

Slingluff, Craig L. ;

Ernstoff, Marc S. ;

Fay, Joseph W. ;

Friedlander, Philip Adam ;

Gajewski, Thomas ;

Zarour, Hassane M. ;

Rotem-Yehudar, Rinat ;

Sosman, Jeffrey Alan .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[5] Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].

Berger, Raanan ;

Rotem-Yehudar, Rinat ;

Slama, Gideon ;

Landes, Shimon ;

Kneller, Abraham ;

Leiba, Merav ;

Koren-Michowitz, Maya ;

Shimoni, Avichai ;

Nagler, Arnon .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051

[6] PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].

Blank, C ;

Brown, I ;

Peterson, AC ;

Spiotto, M ;

Iwai, Y ;

Honjo, T ;

Gajewski, TF .

CANCER RESEARCH, 2004, 64 (03) :1140-1145

[7] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[8] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[9] INTERFERON-ALPHA INCREASES THE FREQUENCY OF INTERFERON-GAMMA-PRODUCING HUMAN CD4+ T-CELLS [J].

BRINKMANN, V ;

GEIGER, T ;

ALKAN, S ;

HEUSSER, CH .

JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (05) :1655-1663

[10] A NEW MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY - CTLA-4 [J].

BRUNET, JF ;

DENIZOT, F ;

LUCIANI, MF ;

ROUXDOSSETO, M ;

SUZAN, M ;

MATTEI, MG ;

GOLSTEIN, P .

NATURE, 1987, 328 (6127) :267-270

← 1 2 3 4 5 6 7 8 9 10 →